ライフサイエンスコーパス: liver transplant recipient

1 t lateral segmental graft for the paediatric liver transplant recipient.

2 eremia due to raw shellfish consumption in a liver transplant recipient.

3 tential interaction of the microbiome in the liver transplant recipient.

4 icity for CMV GI tract disease in kidney and liver transplant recipients.

5 ors is only possible in approximately 20% of liver transplant recipients.

6 rosis especially following HCV recurrence in liver transplant recipients.

7 review three cases of AMR in ABO-compatible liver transplant recipients.

8 its negative impact on long-term survival in liver transplant recipients.

9 ive observational study was conducted in 102 liver transplant recipients.

10 apid fibrosis progression observed in HCV(+) liver transplant recipients.

11 in a longitudinal study of 41 kidney and 33 liver transplant recipients.

12 was performed on whole blood samples of 548 liver transplant recipients.

13 the development of chronic kidney disease in liver transplant recipients.

14 of donor and recipient IL28B genotypes among liver transplant recipients.

15 ported to increase risk of graft failure for liver transplant recipients.

16 d function in the initial recovery period in liver transplant recipients.

17 in healthy, CMV-positive individuals and in liver transplant recipients.

18 and posttransplant hospitalization rates for liver transplant recipients.

19 and early allograft failure in HCV-positive liver transplant recipients.

20 MELD scores and waiting times of liver transplant recipients.

21 ociated with severe recurrent HCV disease in liver transplant recipients.

22 h-degree ACR are decreased in living-related liver transplant recipients.

23 invasive aspergillosis was evaluated in 154 liver transplant recipients.

24 ipients but did not occur in any of the four liver transplant recipients.

25 poor outcome in hepatitis C virus-coinfected liver transplant recipients.

26 enced 14 episodes of hepatic abscess, all in liver transplant recipients.

27 ophylaxis of CMV disease in CMV-seropositive liver transplant recipients.

28 ving trends in invasive fungal infections in liver transplant recipients.

29 donor liver pool available for select adult liver transplant recipients.

30 split-liver transplantation in select adult liver transplant recipients.

31 ciated with increased rates of infection for liver transplant recipients.

32 y detect donor antigen-linked suppression in liver transplant recipients.

33 opment of BCs in a large cohort of pediatric liver transplant recipients.

34 prospective study of EBV infection in adult liver transplant recipients.

35 our experience with the use of daclizumab in liver transplant recipients.

36 adjunct in immunosuppressive strategies for liver transplant recipients.

37 ombocytopenia, has not been fully defined in liver transplant recipients.

38 rus (CMV) disease has not been documented in liver transplant recipients.

39 uent and potentially serious complication in liver transplant recipients.

40 lestatic recurrent hepatitis C in one of the liver transplant recipients.

41 tive reduction with antiviral prophylaxis in liver transplant recipients.

42 isolated unconjugated hyperbilirubinemia in liver transplant recipients.

43 ulted in subtherapeutic daclizumab levels in liver transplant recipients.

44 crolimus (Advagraf) initiation in kidney and liver transplant recipients.

45 nown whether a similar association exists in liver transplant recipients.

46 ransplant recipients and 10%, 9%, and 13% in liver transplant recipients.

47 uracy for the diagnosis of IFIs in high-risk liver transplant recipients.

48 ed with increased morbidity and mortality in liver transplant recipients.

49 to isoniazid for tuberculosis prophylaxis in liver transplant recipients.

50 A cross-sectional study was conducted in 244 liver transplant recipients.

51 treatment of CMV disease, particularly among liver transplant recipients.

52 ts seem to play a key role in non-alcoholic, liver transplant recipients.

53 aring regimens for antifungal prophylaxis in liver transplant recipients.

54 g echinocandins as antifungal prophylaxis in liver transplant recipients.

55 e part of the standard of care for pediatric liver transplant recipients.

56 ic method for GI tract disease in kidney and liver transplant recipients.

57 were assessed in a cohort of 216 consecutive liver-transplant recipients.

58 t-limiting toxic effects in immunosuppressed liver-transplant recipients.

59 ients (715 kidney transplant recipients, 190 liver transplant recipients, 102 lung transplant recipie

60 PCR results were available for 81 kidney and liver transplant recipients; 20 cases of confirmed CMV G

61 nsplant (37 kidney-transplant recipients, 10 liver-transplant recipients, 5 heart-transplant recipien

62 We included 33,668 HCV+ liver transplant recipients (54.0 +/- 7.7 years old, 74.

63 HCV polymerase chain reaction (PCR)-positive liver-transplant recipients (6 with posttransplantation

64 cryptococcosis was significantly higher for liver transplant recipients (adjusted hazard ratio [HR],

65 tive PTLD in an 18-month-old small bowel and liver transplant recipient after one infusion of partial

66 In 70 patients, 36 liver transplant recipients (ages 2-23 years) and 34 hea

67 In addition, in liver transplant recipients, allele 7 was associated wit

68 sted dose in combination with Tac in de novo liver transplant recipients allows CS discontinuation fr

69 ed patient and graft survival rates in adult liver transplant recipients, analyzing outcomes based on

70 h only one case of TMAT, which occurred in a liver transplant recipient and resulted in death from bl

71 ctional, multicenter study that included 344 liver transplant recipients and examined the level of gl

72 vestigated plasma CD154 levels in kidney and liver transplant recipients and found no evidence that C

73 g early have been observed, especially among liver transplant recipients and in cases of graft-transm

74 tial immune suppressive potency in renal and liver transplant recipients and may be safely dosed for

75 immunoregulatory proteogenomic signatures in liver transplant recipients and may therefore facilitate

76 of blood specimens from pediatric and adult liver transplant recipients and normal tissues.

77 infections has been documented previously in liver transplant recipients and patients with cirrhosis.

78 daily doses of interferon were tolerated by liver transplant recipients and provided histological be

79 mportant cause of morbidity and mortality in liver transplant recipients and several different strate

80 llular carcinoma incidence is elevated among liver transplant recipients and subsets of non-liver rec

81 nd actinic keratoses in high-risk kidney and liver transplant recipients and to assess associated fac

82 thrombocytopenia portended a poor outcome in liver transplant recipients and was not related to low T

83 T399I SNPs were assessed in a cohort of 706 liver transplant recipients and were associated with the

84 e of human monocytic ehrlichiosis (HME) in a liver transplant recipient, and review the literature.

85 at the A locus decreases patient survival in liver transplant recipients, and mismatching at the DR a

86 ts does not differ from that of HIV-negative liver transplant recipients, and they suggest that HIV i

87 splant portal vein thrombosis in a cohort of liver transplant recipients, and to identify independent

88 ver transplantation and the implications for liver transplant recipients are not well understood and

89 Pediatric liver transplant recipients arguably have the most to ga

90 -QA instrument, developed and widely used in liver transplant recipients, assesses quality of life (Q

91 ver biopsy specimens obtained from 15 HCV(+) liver transplant recipients at 6 and/or 12 months posttr

92 ective review in a large cohort of pediatric liver transplant recipients at a single institution to d

93 nal status were prospectively assessed in 59 liver transplant recipients at baseline (before transpla

94 ot adequate for prevention of CMV disease in liver transplant recipients at high risk for CMV disease

95 e rate of CMV infection were assessed in 232 liver transplant recipients at our institution during a

96 ed over the last 10 years in 190 consecutive liver transplant recipients at our institution.

97 ble-blind trial of antifungal prophylaxis in liver transplant recipients at risk for invasive fungal

98 xpression in liver tissue and serum of adult liver transplant recipients before, early, and late afte

99 UCLA's experience with PTLD in all pediatric liver transplant recipients between 1984-1997.

100 l, data were collected from 1799 consecutive liver transplant recipients between January 1, 2002, and

101 The postoperative clinical course of 212 liver transplant recipients between January 2008 and Apr

102 surgical technique and medical management of liver transplant recipients, biliary complications remai

103 nd graft survival between obese and nonobese liver transplant recipients, but obesity presents import

104 cause significant morbidity and mortality in liver transplant recipients, but the need and best agent

105 HLA-A2 and A3 were isolated from the sera of liver transplant recipients by affinity chromatography.

106 Liver transplant recipients can be converted from twice-

107 Our data is encouraging and shows that if liver transplant recipients can tolerate treatment for 1

108 ity would significantly advance personalized liver transplant recipient care and management of immuno

109 Lesions tended to occur earlier in the liver transplant recipients, compared with other organ t

110 Perioperative renal dysfunction in liver transplant recipients complicates maintenance immu

111 Assigning a morphometric age to potential liver transplant recipients could improve prediction of

112 We aggregated national liver transplant recipient data between 2005 and 2009 to

113 udy was performed on a selected cohort of 40 liver transplant recipients derived from the previous pr

114 The MELD scores and waiting time of liver transplant recipients differed by transplantation

115 score at transplantation and waiting time of liver transplant recipients differs by transplantation c

116 ndings suggest that survival of HIV-positive liver transplant recipients does not differ from that of

117 imus induced active TGFbeta1 blood levels in liver transplant recipients during a follow up period of

118 lood and liver tissue samples collected from liver transplant recipients enrolled in a prospective mu

119 iRNA) profiling in 318 serum samples from 69 liver transplant recipients enrolled in the Immune Toler

120 Liver transplant recipients experienced a significant 70

121 roborated by sequence analyses of HCV from a liver transplant recipient experiencing viral breakthrou

122 d Transplantation Network database of 52,435 liver transplant recipients from 1995 through 2005.

123 y of Transplant Recipients for primary adult liver transplant recipients from 2001 to 2009.

124 followed serum DSA levels of 90 consecutive liver transplant recipients from baseline to 4 months.

125 d graft survival was significantly worse for liver transplant recipients from donors with ITP compare

126 ecipients from donors with ITP compared with liver transplant recipients from donors without ITP (64%

127 dialysis data, we assembled a cohort of 4997 liver transplant recipients from February 27, 2002-Janua

128 ewed the clinical charts of kidney or kidney/liver transplant recipients from January 2005 to Decembe

129 Among young first isolated liver transplant recipients, graft failure risks are hig

130 In 1997-2002, 4.6% of liver transplant recipients had HCC compared with 26% in

131 , previous analysis of human bone marrow and liver transplant recipients has demonstrated that platel

132 The prevalence of alcohol use among Finnish liver transplant recipients has not been studied before.

133 lae associated with cytomegalovirus (CMV) in liver-transplant recipients has not been clearly delinea

134 of human herpesvirus-6 (HHV-6) infection in liver transplant recipients, has not been fully discerne

135 Liver transplant recipients have a high prevalence of ri

136 se that occurs despite CMV prophylaxis among liver transplant recipients have been incompletely defin

137 tors, and outcome of invasive candidiasis in liver transplant recipients have changed.

138 Although short-term studies of elderly liver transplant recipients have demonstrated that the i

139 r fibrosis progression among black and white liver transplant recipients have not been investigated.

140 persons who receive solid organ transplants, liver transplant recipients have the highest incidence o

141 Centers with >30% of their liver transplant recipients hospitalized >/=30 days in t

142 n in invasive fungal infections in high-risk liver transplant recipients, i.e., those requiring renal

143 r, other studies showed a high prevalence in liver transplant recipients immediately after, or some t

144 Mycobacterium llatzerense that occurred in a liver transplant recipient in the midwestern United Stat

145 is a significant disparity in MELD scores in liver transplant recipients in small vs large OPOs; fewe

146 hort study analyzed all adult deceased donor liver transplant recipients in the Scientific Registry o

147 serum and plasma samples were obtained from liver transplant recipients in the UK trial of tacrolimu

148 al of all adult, first-time, deceased-donor, liver transplant recipients in the United States since t

149 titis C virus (HCV)-specific CD8+ T cells in liver transplant recipients in whom the allograft is HLA

150 Few data exist in liver transplant recipients, in whom exercise should be

151 fective for the prevention of CMV disease in liver transplant recipients, including high-risk patient

152 romboembolic events across a wide variety of liver transplant recipients, including those at low risk

153 Liver transplant recipients infected with hepatitis C vi

154 In hepatitis C virus (HCV)-positive liver transplant recipients, infection of the allograft

155 anciclovir-based chemoprophylaxis for CMV in liver transplant recipients is cost-effective by current

156 ormed donor-specific HLA antibodies (DSA) in liver transplant recipients is increasingly recognized;

157 therapy for cytomegalovirus (CMV) disease in liver transplant recipients is not known.

158 nfections remain a significant problem among liver transplant recipients (LTRs).

159 in eight HTRs (ages 57 +/- 6 years) and six liver-transplant recipients (LTRs) (ages 52 +/- 2 years)

160 ansplant recipients, but fewer data exist on liver-transplant recipients (LTRs).

161 Operationally tolerant pediatric liver transplant recipients maintain generally stable al

162 from the case notes of 181 consecutive adult liver transplant recipients (median follow-up 54 months)

163 A total of 592 liver transplant recipients met the inclusion criteria;

164 In an open-label, multicenter study, stable liver transplant recipients (n=69) were converted from t

165 herapy were prospectively investigated in 33 liver transplant recipients not given antiviral prophyla

166 9.0; 95% confidence interval, 1.8-45.8) and liver transplant recipients (odds ratio, 12.1; 95% confi

167 s little is known about the opinion of Dutch liver transplant recipients on anonymity of organ donati

168 lood mononuclear cells from a group of eight liver transplant recipients, one of whom had stopped all

169 Among liver transplant recipients, only two of 20 patients rec

170 The living-donor liver transplant recipient operation has undergone signi

171 Three groups of stable liver transplant recipients: operationally tolerant (TOL

172 Records of all adult liver transplant recipients over 4 years were reviewed (

173 Sixty-four percent of liver transplant recipients overall experience a decreas

174 relapse after treatment of CMV disease were liver transplant recipients, patients with ganciclovir-r

175 ained suppression of HCV replication in this liver transplant recipient provides great promise for th

176 In the United States, 5% of adult liver transplant recipients receive a graft donation aft

177 an important one because the benefits to the liver transplant recipient receiving a kidney transplant

178 clearance of disseminated ADV infection in a liver transplant recipient receiving CDV infusions.

179 98 to November 2001, 81 pediatric orthotopic liver transplant recipients receiving 89 liver grafts we

180 eceptor 1 gene, Angiotensinogen gene) in 233 liver transplant recipients receiving Cyclosporine (CsA)

181 Pediatric liver transplant recipients receiving primary tacrolimus

182 hronic rejection does not occur in pediatric liver transplant recipients receiving tacrolimus-based i

183 galactomannan (GM) and beta-D-glucan (BG) in liver transplant recipients remains uncertain.

184 invasive fungal infections, directed toward liver transplant recipients requiring renal replacement

185 cii pneumonia (PCP) occurred among renal and liver transplant recipients (RTR and LTR) in the largest

186 file of biomarkers that predict tolerance in liver transplant recipients (see the related article beg

187 nt randomized phase III study of 719 de novo liver transplant recipients showed that early everolimus

188 Of 72 consecutive liver transplant recipients studied, CMV antigenemia occ

189 There were 50 consecutive liver transplant recipients studied.

190 present data from a retrospective review in liver-transplant recipients suffering from HCV recurrenc

191 In HCV-positive liver transplant recipients, the liver graft is colonize

192 lobe living-donor hepatectomies for 95 adult liver-transplant recipients, the largest single institut

193 ence of viral infections and malignancies in liver transplant recipients, this gene set provides an i

194 ized multicenter open-label trial in de novo liver transplant recipients to assess the feasibility an

195 We retrospectively studied kidney and kidney/liver transplant recipients to estimate their POAF incid

196 al assays before and after SRL conversion in liver transplant recipients to test for enhanced markers

197 analysis in operationally tolerant pediatric liver transplant recipients (TOL), those undergoing pros

198 operational tolerance in pediatric and adult liver transplant recipients, transcriptional profiles we

199 Despite this, the long-term outcomes of HCV+ liver transplant recipients transplanted from HCV+ donor

200 Our aim is to evaluate long-term outcomes in liver transplant recipients transplanted with HCV antibo

201 tcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monot

202 he same eligibility criteria consisted of 50 liver transplant recipients treated with our standard Ta

203 ce of 30% to 37% in kidney and 44% to 45% in liver transplant recipients treated with tacrolimus.

204 rs for new-onset diabetes mellitus (NODM) in liver transplant recipients using the Organ Procurement

205 f virus by culture in patients only when the liver transplant recipient was CMV immune before transpl

206 le-institution database of 1,446 consecutive liver transplant recipients was conducted.

207 registry and Medicare claims data for 12,803 liver transplant recipients was developed to capture inf

208 rmine whether isolated hyperbilirubinemia in liver transplant recipients was due to Gilbert's syndrom

209 Hepatocellular carcinoma incidence among liver transplant recipients was elevated overall (SIR 3.

210 e tolerability of daily interferon dosing in liver transplant recipients was evaluated and effects on

211 A hypothetical cohort of liver transplant recipients was followed up for a year p

212 A retrospective analysis of 396 liver transplant recipients was performed at the Medical

213 A prospective study of 80 consecutive liver transplant recipients was performed using surveill

214 le-center study of 137 consecutive pediatric liver transplant recipients was to examine the effect of

215 In orthotopic liver transplant recipients we found a 26% incidence of

216 is single-center study of 88 consecutive DCD liver transplant recipients were (1) to compare renal ou

217 Forty-four thousand seven hundred fifty-six liver transplant recipients were analyzed.

218 n studies reporting outcomes for DCD and DBD liver transplant recipients were considered.

219 Cadaveric liver transplant recipients were enrolled from January 2

220 Thirty consecutive liver transplant recipients were enrolled in this prospe

221 Eighty-eight liver transplant recipients were included in this study.

222 kidney transplant recipients and 20 cases in liver transplant recipients were included.

223 Liver transplant recipients were more likely to have dis

224 Adult liver transplant recipients were randomized on the day o

225 In this clinical trial, 129 liver transplant recipients were randomized to be monito

226 A total of 2050 liver transplant recipients were studied, of these 960 (

227 udy, serial blood samples from 689 kidney or liver transplant recipients were tested for CMV DNA by q

228 Fifty-seven liver-transplant recipients were included, 29 naive (gro

229 (13 bone marrow transplant recipients and 1 liver transplant recipient) were reviewed.

230 viral growth during infection of HCMV-naive liver transplant recipients, whereas lower efficacy leve

231 thern California to create a database of 598 liver transplant recipients, which incorporates diagnost

232 scribe the first case in the literature of a liver transplant recipient who developed an infrarenal a

233 ssociated visceral angioedema occurring in a liver transplant recipient who presented with acute-onse

234 We describe the case of a liver transplant recipient who presented with an acute f

235 We present the first adult liver transplant recipient who received prophylactic vac

236 single-center retrospective analysis of 207 liver transplant recipients who achieved MELD score of 4

237 Liver transplant recipients who developed CMV disease ha

238 but is similar to what would be expected in liver transplant recipients who did not have ESRD.

239 with CMV culture technique in a cohort of 40 liver transplant recipients who did not receive antivira

240 ubjects consisted of 27 hepatitis C-infected liver transplant recipients who had liver biopsy specime

241 disease is an important clinical problem in liver transplant recipients who receive antiviral prophy

242 ecember 1997, all CMV seropositive renal and liver transplant recipients who received ALA therapy wer

243 risk factors for CMV disease in a cohort of liver transplant recipients who received antiviral proph

244 the first posttransplant year in a cohort of liver transplant recipients who received antiviral proph

245 ologic injury due to histoincompatibility in liver transplant recipients who received sequential kidn

246 ttransplant) was assessed in 120 consecutive liver transplant recipients who survived at least 6 mont

247 initiation of isoniazid chemoprophylaxis in liver transplant recipients who test positive on the tub

248 In conclusion, pediatric liver transplant recipients who undergo transfer to the

249 OS did not differ between liver transplant recipients who were not pretreated or p

250 Pediatric liver transplant recipients who were successfully withdr

251 and quantified the circulating ApoL1 in two liver transplant recipients whose native APOL1 genotype

252 psy-proven regression of liver fibrosis in a liver transplant recipient with cirrhosis after chronic

253 inimal transient side effects in a pediatric liver transplant recipient with disseminated adenoviral

254 of an interferon-free, all oral regimen in a liver transplant recipient with severe recurrent HCV.

255 er-related death, or retransplantation among liver transplant recipients with a CC genotype donor.

256 Between 1996 and 2002, 33 liver transplant recipients with a clinical suspicion of

257 We reviewed all records of adult kidney and liver transplant recipients with a GI tract biopsy and p

258 are leading causes of long-term mortality in liver transplant recipients with ALD or NAFLD.

259 in the tubulointerstitium of kidneys from 15 liver transplant recipients with biopsy-confirmed chroni

260 stochemical analyses of kidney biopsies from liver transplant recipients with chronic CsA nephrotoxic

261 C57BL/6 J wild type and Nox2-/- mice, and in liver transplant recipients with chronic CsA nephrotoxic

262 g three times daily) in 303 CMV-seronegative liver transplant recipients with CMV-seropositive donors

263 of CMV disease in high-risk CMV-seronegative liver transplant recipients with CMV-seropositive donors

264 Cytomegalovirus (CMV)-seronegative liver transplant recipients with CMV-seropositive donors

265 large report of DC as a viable strategy for liver transplant recipients with coagulopathy or hemodyn

266 ciated conditions that are being provided to liver transplant recipients with diabetes have not yet b

267 In liver transplant recipients with Epstein-Barr virus (EBV

268 The medical records of four liver transplant recipients with gastric MALT lymphoma w

269 th a short course (in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 I

270 ransplantation survival of adult, first-time liver transplant recipients with HCC (n = 9135) or witho

271 PGB in 138 consecutive adult, deceased donor liver transplant recipients with HCC.

272 ecipients (1995-2013), we selected all adult liver transplant recipients with HCV, and cross-sectiona

273 presentation, treatment, and outcome of four liver transplant recipients with Helicobacter pylori-ass

274 ecember 19, 2011 and January 25, 2013, seven liver transplant recipients with hepatitis C received be

275 A retrospective review of adult liver transplant recipients with hepatitis C receiving b

276 ucted a multicenter case-control study of 52 liver transplant recipients with hepatitis C to assess t

277 Thirty-five consecutive liver transplant recipients with invasive candidiasis we

278 Thirty-one HCV-seropositive liver transplant recipients with long-term follow-up wer

279 In this cohort of liver transplant recipients with long-term follow-up, no

280 nt trend toward the use of elderly donors in liver transplant recipients with low model of end-stage

281 tric bypass can be successfully performed in liver transplant recipients with morbid obesity and may

282 Liver transplant recipients with NASH have a higher risk

283 novo post-transplant type 2 diabetes (DM) in liver transplant recipients with NASH.

284 ed a retrospective cohort study of 749 adult liver transplant recipients with pre- and posttransplant

285 Liver transplant recipients with recurrent HCV (elevated

286 osuppression regimen in hepatitis C-positive liver transplant recipients with renal dysfunction, and

287 lowing liver transplantation alone or SLK in liver transplant recipients with renal dysfunction.

288 to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction.

289 It is important to avoid PEG therapy in liver transplant recipients with specific clinical, bioc

290 Liver transplant recipients with type 1 or CAD have appr

291 Liver-transplant recipients with CMV infection, includin

292 ution that must be taken when treating HCV-R liver-transplant recipients with combination pegylated a

293 We enrolled 34 liver-transplant recipients with no fibrosis or mild fib

294 h rate of sustained virologic response among liver-transplant recipients with recurrent HCV genotype

295 merase inhibitor dasabuvir, and ribavirin in liver-transplant recipients with recurrent HCV genotype

296 Daclizumab used in liver transplant recipients without any CI was ineffecti

297 oing LTx have a reduced survival compared to liver transplant recipients without explant iron excess.

298 and these cases were compared to 41 matched liver transplant recipients without increased hepatic ir

299 ong-term treatment with ribavirin is safe in liver transplant recipients, without achieving HEV susta

300 However, most liver transplant recipients would like to receive some g